Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas

Author： Stroppa Elisa   Bertuzzi Alexia   Comite Gabriele   Mussi Chiara   Lutman Romano   Barbato Alfredo   Santoro Armando  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.28, Iss.6, 2010-12, pp. : 834-838

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide

By Yoo Changhoon   Lee Jeeyun   Rha Sun   Park Kyong   Kim Tae   Kim Yu   Lee Hyo   Lee Kyung   Ahn Jin-Hee  

Investigational New Drugs, Vol. 31, Iss. 6, 2013-12 ,pp. : 1602-1608

Springer Publishing Company

Access to resources Recommend Favorite

A non-comparative phase II study of dose intensive chemotherapy with doxorubicin and ifosfamide followed by high dose ICE consolidation with PBSCT in non-resectable, high grade, adult type soft tissue sarcomas

By Hartmann Jörg   Horger M.   Kluba T.   Königsrainer A.   Zwart P.   Weyhern C.   Eckert F.   Budach W.   Bokemeyer C.  

Investigational New Drugs, Vol. 31, Iss. 6, 2013-12 ,pp. : 1592-1601

Springer Publishing Company

Access to resources Recommend Favorite

Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx®) in combination with topotecan in patients with advanced malignancies

By Ghesquières Hervé   Faivre Sandrine   Djafari Latifa   Pautier Patricia   Lhommé Catherine   Lozahic Stéphanie   Djazouli Kamel   Armand Jean-Pierre   Raymond Eric  

Investigational New Drugs, Vol. 24, Iss. 5, 2006-09 ,pp. : 413-421

Springer Publishing Company

Access to resources Recommend Favorite

Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study

By Martín-Liberal J.   López-Pousa A.   Broto J.   Cubedo R.   Gallego O.   Brendel E.   Tirado O.   Muro X.  

Investigational New Drugs, Vol. 32, Iss. 2, 2014-04 ,pp. : 287-294

Springer Publishing Company

Access to resources Recommend Favorite

Combination of rituximab and nonpegylated liposomal doxorubicin (R‐NPLD) as front‐line therapy for aggressive non‐Hodgkin lymphoma (NHL) in patients 80 years of age or older: a single‐center retrospective study

By  

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 44-48

John Wiley & Sons Inc

Access to resources Recommend Favorite